Tempus AI (NASDAQ:TEM) Price Target Lowered to $60.00 at JPMorgan Chase & Co.

Tempus AI (NASDAQ:TEM) had its price objective decreased by investment analysts at JPMorgan Chase & Co. from $80.00 to $60.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 10.85% from the company’s previous close.

TEM has been the subject of a number of other reports. BTIG Research cut their target price on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Mizuho started coverage on shares of Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price on the stock. Piper Sandler dropped their price target on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Finally, Needham & Company LLC reduced their price objective on Tempus AI from $100.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.92.

Tempus AI Price Performance

Shares of NASDAQ:TEM traded down $3.82 during mid-day trading on Wednesday, reaching $54.13. The stock had a trading volume of 6,627,362 shares, compared to its average volume of 5,707,368. The business’s 50 day moving average price is $61.92 and its 200 day moving average price is $73.59. Tempus AI has a 1 year low of $36.22 and a 1 year high of $104.32. The company has a market cap of $9.63 billion, a P/E ratio of -45.47 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the transaction, the chief executive officer owned 8,941,533 shares of the company’s stock, valued at approximately $586,206,903.48. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 596,035 shares of company stock valued at $37,505,125. 26.27% of the stock is owned by company insiders.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in the business. Cranbrook Wealth Management LLC bought a new position in shares of Tempus AI in the third quarter worth about $25,000. JPL Wealth Management LLC purchased a new stake in Tempus AI in the 3rd quarter valued at about $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI in the 4th quarter valued at about $27,000. GAMMA Investing LLC bought a new position in Tempus AI in the 3rd quarter worth about $28,000. Finally, Allworth Financial LP increased its position in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Very strong revenue growth — Q4 revenue jumped ~83% YoY, beating consensus and showing broad strength across Diagnostics, MRD and Data businesses; RCV and retention metrics also look healthy. MarketBeat Q4 recap
• Positive Sentiment: FY‑2026 revenue guide is sizable — management outlined roughly $1.59B in 2026 revenue (≈25% growth guidance), which implies continued top‑line momentum and gives a clear growth runway to model. Seeking Alpha: 2026 revenue target
• Positive Sentiment: Margins improving — management reported narrower losses, higher gross profit and an adjusted EBITDA inflection to positive on a YoY basis, supporting the path to eventual sustained profitability. MarketBeat analysis
• Neutral Sentiment: Product/partnership expansion continues — launches like the HRD‑RNA algorithm and a lung‑screening partnership expand addressable market and could support longer‑term revenue, but near‑term financial impact is incremental. Yahoo Finance: product & partnership update
• Neutral Sentiment: Analysts largely remain constructive — several firms kept Buy/Overweight ratings (Morgan Stanley kept a $85 PT; Canaccord and others reiterated positives), showing institutional support despite the pullback. TipRanks: analyst notes
• Negative Sentiment: Profitability details disappointed some investors — headlines and market reaction focused on a wider‑than‑expected loss / operating shortfall in Q4 and ambiguity on the timing of full‑year profitability inflection, which undercut sentiment. Zacks: earnings miss / reaction
• Negative Sentiment: Price‑target cut and valuation concerns — BTIG trimmed its target from $105 to $90 (still constructive), highlighting mixed near‑term expectations; high leverage and elevated short interest add downside risk in volatile trading. Benzinga: BTIG target cut
• Negative Sentiment: Market reaction: despite beat‑and‑raise elements, investors sold on the mixed profit signal and cautious tone — that combination explains today’s pullback. 247WallSt: mixed reaction

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.